GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Foghorn Therapeutics
Foghorn Therapeutics is a biotech company working in the cutting-edge field of epigenetics. Its stock price is a venture bet that its scientific platform will lead to the creation of a new class of cancer drugs. The chart reflects high volatility and reliance on research data.
Share prices of companies in the market segment - Cancer blood
Foghorn Therapeutics (FHTX) is a biotech company developing a new class of drugs targeting the chromatin remodeling system for the treatment of oncological diseases, particularly hematological ones. We classify it as "Blood Cancer." The chart below shows the dynamics in this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Foghorn Therapeutics is a biotech company developing a new class of drugs that target the chromatin regulatory system for the treatment of cancer. Its cutting-edge science makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Foghorn compares to it.
Change in the price of a company, segment, and market as a whole per day
FHTX - Daily change in the company's share price Foghorn Therapeutics
Foghorn, an oncology company, is extremely volatile. Change_co measures market reaction to preclinical and clinical trial data. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer blood
Foghorn Therapeutics Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with FHTX's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Foghorn is a biopharmaceutical company developing cancer treatments. Oncology is a highly volatile sector driven by clinical trial results. The chart below shows the average fluctuations in this industry, providing context for evaluating Foghorn shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Foghorn Therapeutics
Foghorn Therapeutics' year-to-date performance is a story of developing a new class of oncology drugs targeting the gene regulatory system. Its 12-month market cap is entirely dependent on progress in early clinical trials and partnerships with major pharmaceutical companies like Eli Lilly, confirming the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Cancer blood
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company developing a new class of drugs that modulate gene expression for the treatment of cancer. Its stock price reflects the enormous potential of its breakthrough scientific platform and the high risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Foghorn Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Foghorn Therapeutics
Foghorn, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its oncology drugs based on its unique platform, which determines its future.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Oncology biotechnology, which targets fundamental genetic mechanisms, is at the cutting edge of science. The dynamics of this sector, as seen in the chart, reflect the high degree of risk and investor confidence in scientific breakthroughs. Foghorn Therapeutics is a company active in this field.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Foghorn Therapeutics is an early-stage oncology company. Its shares exist in a world of their own: their price rises and falls based on research data, paying little attention to overall market trends. The chart illustrates this disconnect.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Foghorn Therapeutics
Shares of Foghorn Therapeutics, a biopharmaceutical company focused on gene regulation in oncology, are extremely volatile. Weekly price movements are driven by news about clinical trials and scientific publications. The chart below illustrates how short-term events and investor expectations shape value in innovative medicine.
Weekly dynamics of market capitalization of the market segment - Cancer blood
How does Foghorn Therapeutics' performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements, driven by news about its unique gene regulation platform, with the overall trend. This helps us understand whether the stock's movement is the result of a unique scientific event or a reflection of general sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Foghorn Therapeutics operates in the world of oncology research, where clinical trial data is king. This chart shows how its weekly stock price can completely defy broader market trends, reacting sharply to company-specific scientific news rather than the S&P 500.
Market capitalization of the company, segment and market as a whole
FHTX - Market capitalization of the company Foghorn Therapeutics
Foghorn Therapeutics' market capitalization reflects investors' bets on its cutting-edge gene regulation platform for cancer drug development. As a clinical-stage company, its valuation is highly sensitive to research results. The chart clearly demonstrates the high volatility and hopes associated with biotech breakthroughs.
FHTX - Share of the company's market capitalization Foghorn Therapeutics within the market segment - Cancer blood
Foghorn Therapeutics is a biotech company whose market share is based on its pioneering platform for gene expression regulation. Its market capitalization reflects the potential of its approach to developing a new class of drugs for the treatment of cancer and other diseases.
Market capitalization of the market segment - Cancer blood
The chart below is a barometer of the oncology-focused biotech sector. Its dynamics reflect the hopes and disappointments in the search for new drugs. Foghorn Therapeutics, with its gene regulation platform, is part of this ecosystem, where every success can add billions to the overall value.
Market capitalization of all companies included in a broad market index - GURU.Markets
This line on the chart represents the market valuation of a groundbreaking scientific approach to cancer treatment. Foghorn Therapeutics' market capitalization fluctuates depending on news about its gene regulation platform. Its share of the global economy represents the potential value of this new cancer treatment.
Book value capitalization of the company, segment and market as a whole
FHTX - Book value capitalization of the company Foghorn Therapeutics
Foghorn Therapeutics' book value represents its scientific capital. The chart below reflects the value of its unique Gene Traffic Control® platform and its oncology pipeline. Growth in the pipeline signals research success, which is the primary tangible embodiment of this biotech company's value.
FHTX - Share of the company's book capitalization Foghorn Therapeutics within the market segment - Cancer blood
Foghorn Therapeutics's core assets are not factories, but cutting-edge scientific laboratories dedicated to researching the genetic basis of cancer. The chart reflects the company's share of this capital-intensive scientific infrastructure, which serves as the physical foundation for the development of breakthrough cancer treatments.
Market segment balance sheet capitalization - Cancer blood
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Foghorn Therapeutics, as a clinical-stage biotech, appears "light." Its value lies in its scientific platform and patents, not in large manufacturing plants. Its modest balance sheet contrasts with the high potential value of its developments.
Book value of all companies included in the broad market index - GURU.Markets
Foghorn Therapeutics doesn't manufacture drugs on an industrial scale; its assets are a scientific platform and intellectual property in the field of genetic regulation. The company's balance sheet represents the value of the "key" to new cancer treatments. Compared to the entire material economy in the chart, Foghorn represents a concentrated scientific bet on the future of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Foghorn Therapeutics
Foghorn's balance sheet is the value of its labs. Its market capitalization is the price of the hope that their scientific platform will be able to "reprogram" genes to fight cancer. The MvsBCap_Co chart shows how much this complex scientific "dream" is worth compared to the cost of actual lab equipment.
Market to book capitalization ratio in a market segment - Cancer blood
Foghorn Therapeutics is a biotech company working on a new class of cancer drugs. Its value lies solely in its scientific platform. The chart shows the enormous premium the market places on its potential discoveries, many times greater than the value of its lab equipment.
Market to book capitalization ratio for the market as a whole
Foghorn Therapeutics is a biotech company developing a new class of drugs to treat cancer by targeting the gene expression regulatory system. Its value lies in its scientific platform and the potential for future drugs. This chart demonstrates why investors are willing to pay a high premium for breakthrough scientific approaches, even if the tangible assets are minimal.
Debts of the company, segment and market as a whole
FHTX - Company debts Foghorn Therapeutics
Foghorn Therapeutics, a biopharmaceutical company, has a debt strategy focused on funding cutting-edge scientific research. This chart illustrates how the company is raising capital to develop a new class of cancer drugs. In this research-intensive industry, debt is a vital resource for conducting lengthy and expensive clinical trials.
Market segment debts - Cancer blood
Foghorn Therapeutics is a biotech company working on a new class of cancer drugs. At the clinical stage, when the company has no revenue yet, its survival depends entirely on its ability to fund long-term, expensive research. This chart shows the company's financial strategy to support its research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Foghorn Therapeutics
For Foghorn Therapeutics, a biotech company working on cancer treatments, debt is often a way to finance lengthy and expensive research. This chart shows its reliance on debt capital. A high debt load increases risks, as if clinical trials fail, the company may not have the revenue to repay.
Market segment debt to market segment book capitalization - Cancer blood
Foghorn Therapeutics is a clinical-stage biotech company whose oncology research requires significant investment. Debt can be a tool for funding trials. The chart shows how the company's leverage, used to advance its scientific platform, compares to the market capitalization and risks of the overall biotech sector.
Debt to book value of all companies in the market
Foghorn Therapeutics (FHTX) is a biotech company developing cancer treatments. Research-stage companies like these are often financed with equity rather than debt. This chart shows the overall debt burden of the economy. This analysis helps us understand how FHTX's financial strategy differs from that of mature companies with high debt burdens.
P/E of the company, segment and market as a whole
P/E - Foghorn Therapeutics
This chart shows the valuation of Foghorn Therapeutics, a clinical-stage biopharmaceutical company. The price-to-earnings ratio is either absent or irrelevant, as the company is focused on research rather than profits. Its value reflects investors' bet on the success of its scientific platform in gene regulation for the development of new cancer drugs.
P/E of the market segment - Cancer blood
This chart illustrates the average P/E for biotech companies. For Foghorn Therapeutics, a research-stage company, it serves as a benchmark. Although the company itself doesn't have a P/E, this metric reflects the overall level of optimism in the sector. It shows how highly investors, on average, value the scientific potential that underlies Foghorn's value.
P/E of the market as a whole
Foghorn Therapeutics is a biotech company developing a new class of drugs that target gene regulation systems to treat cancer. This cutting-edge science has the potential to transform therapeutic approaches. This risk appetite chart helps understand how the overall market values long-term and breakthrough projects in oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotechnology company developing a new class of drugs targeting the gene expression regulatory system. This chart reflects investor expectations for its scientific platform. The valuation is entirely dependent on future clinical trial results and the potential of its drugs for the treatment of oncology.
%20P%2FE%20Foghorn%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Foghorn-Therapeutics&v=1772675368780 "Chart of the company's future (projected) P/E Foghorn Therapeutics")
Future (projected) P/E of the market segment - Cancer blood
Foghorn Therapeutics is a biotech company developing drugs by targeting gene regulation. This chart reflects the company's long-term profitability expectations relative to other biotech companies. It shows how highly the market values the potential of their scientific platform for developing breakthrough cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772675368808 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Foghorn Therapeutics is a biotech company working on a new class of cancer drugs. Its success depends on scientific breakthroughs, not the state of the economy. This chart of overall market expectations is important to Foghorn as an indicator of investor risk appetite. Market optimism facilitates raising the capital needed for long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772675368816 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotechnology company developing a new class of cancer drugs targeting gene regulation. Its financial performance fully reflects its R&D expenditures. This chart illustrates the risky and capital-intensive process of developing innovative oncology drugs.
Profit of companies in the market segment - Cancer blood
Foghorn Therapeutics is developing a new class of cancer drugs that regulate gene expression. The company's financial performance reflects its massive investment in early-stage research. This chart for the biotech sector shows a collective bet on future breakthroughs, where current losses are the price of potentially huge profits if successful.
Overall market profit
Foghorn Therapeutics is a biotech company developing a new class of cancer drugs that target the gene regulatory system. Its value is entirely dependent on the success of this cutting-edge science. The overall economic situation, reflected in this chart, influences financial markets, which influence the company's ability to raise capital for its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Foghorn Therapeutics
Foghorn Therapeutics is a biotech company developing a new generation of cancer drugs based on chromatin research. This chart reflects analyst expectations, which at this stage are driven not by sales but by progress in clinical trials. Positive data could dramatically change forecasts for the company's future value.
%20profit%20of%20the%20company%20Foghorn%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Foghorn-Therapeutics&v=1772675368906 "Graph of future (projected) profit of the company Foghorn Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer blood
Foghorn Therapeutics is a biotechnology company developing a new class of drugs to treat blood cancers through chromatin modulation. This chart reflects revenue projections for the entire oncology segment. It helps assess the overall investment climate and expectations for breakthroughs in cancer treatment, which are important context for assessing the potential of Foghorn's cutting-edge science.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772675368921 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Foghorn Therapeutics is a clinical-stage biotech company developing cancer treatments. Its success depends on scientific breakthroughs and funding. The overall investment climate, which can be assessed using this chart, is critical. During periods of economic growth, capital availability for risky biotech projects is significantly higher.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772675368967 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotech developing a new generation of cancer drugs. It has virtually no revenue from product sales. This chart shows how investors value its scientific platform, not its current sales. This valuation reflects their belief in the multibillion-dollar potential of future breakthrough drugs.
P/S market segment - Cancer blood
Foghorn Therapeutics is a biotechnology company developing a new class of drugs targeting the gene expression regulatory system. Its primary focus is on the treatment of cancer, particularly hematological malignancies. This chart shows the average valuation in the sector, which helps understand the market premium placed on Foghorn's innovative scientific platform.
P/S of the market as a whole
Foghorn Therapeutics is a biotech company developing a new class of cancer drugs by targeting the gene regulatory system. This cutting-edge science carries high risk and potentially huge rewards. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotech developing cancer drugs. Without current revenue, its valuation is based entirely on future expectations. This chart reflects investors' faith in the company's scientific platform and the potential commercial success of its drugs if approved by regulators.
%20P%2FS%20Foghorn%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Foghorn-Therapeutics&v=1772675369092 "The graph of the company's future (projected) P/S Foghorn Therapeutics")
Future (projected) P/S of the market segment - Cancer blood
Foghorn Therapeutics is a biopharmaceutical company developing a new class of drugs targeting the gene expression regulatory system. This chart compares market expectations for its future revenue with other companies working in the field of blood cancer treatment. This valuation reflects investor confidence in its breakthrough scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772675369137 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Foghorn Therapeutics is a biotech company at the forefront of cancer research. Its success depends not on economic cycles, but on scientific breakthroughs. However, the overall optimism reflected in the chart creates a favorable environment for raising the capital needed to conduct expensive clinical trials that could change patients' lives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772675369197 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Foghorn Therapeutics
Foghorn Therapeutics is a clinical-stage biotech company developing a new generation of cancer drugs. Its revenue at this stage comes not from sales but from payments from large pharmaceutical partners for collaborative research. The chart shows the amount of this funding, which allows the company to advance its innovative scientific platform.
Sales of companies in the market segment - Cancer blood
Foghorn Therapeutics is a biotech company at the forefront of epigenetics. It is developing a new class of cancer drugs targeting the chromatin regulatory system. Currently, revenue is generated through partnerships with major pharmaceutical companies. This chart reflects investments in oncology, where breakthrough platforms like Foghorn are raising capital.
Overall market sales
Foghorn Therapeutics is a clinical-stage biotech company developing cancer treatments. Its success depends on research results, not economic cycles. However, the overall economic situation, reflected in this chart, influences investor sentiment and their willingness to fund long-term, risky biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Foghorn Therapeutics
Foghorn Therapeutics is a biotech company developing a new class of drugs to treat cancer by targeting gene regulation. The company's future depends on the success of its clinical trials. This chart shows analysts' assessments of the potential of Foghorn's scientific platform and the likelihood of commercialization of its oncology drug candidates.
%20sales%20of%20the%20company%20Foghorn%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Foghorn-Therapeutics&v=1772675369293 "Schedule of future (projected) sales of the company Foghorn Therapeutics")
Future (projected) sales of companies in the market segment - Cancer blood
Foghorn Therapeutics is a biotech company developing a new class of drugs to treat cancer by targeting gene regulation. This chart shows the outlook for the oncology sector. It allows one to assess whether Foghorn's innovative scientific approach could lead to a breakthrough that would fundamentally change its outlook, given overall trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772675369307 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Foghorn Therapeutics is a biotechnology company developing a new generation of cancer drugs by targeting gene regulation. This chart, reflecting overall economic sentiment, influences the company through the investment climate. A stable economy and investor interest in biotechnology provide Foghorn with access to capital for costly research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772675369418 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Foghorn Therapeutics
Foghorn Therapeutics is at the forefront of the fight against cancer, developing drugs that target the genetic mechanisms of disease. Currently, the company's business is driven by massive investments in research. This chart reflects not current profits, but the value of innovations and scientific research that could radically change treatment approaches in the future.
Market segment marginality - Cancer blood
Foghorn Therapeutics is a biotech company developing a new generation of cancer drugs based on its Gene Traffic Control® platform. At the clinical stage, the data in this chart reflects not revenue but the intensity of research investment. This demonstrates how actively the company is investing in its scientific platform compared to its oncology competitors.
Market marginality as a whole
Foghorn Therapeutics is a biotech company developing a new class of drugs targeting the gene regulatory system for the treatment of cancer. The overall profitability picture is irrelevant to them. Their value lies in the potential of their innovative scientific platform. Success depends entirely on clinical trial results, not on general economic trends.
Employees in the company, segment and market as a whole
Number of employees in the company Foghorn Therapeutics
Foghorn Therapeutics is a biotech company working on a new class of cancer drugs. This chart shows the size of its research team, which is its primary asset. The growth of this intellectual capital directly reflects investment in the scientific platform and progress in advancing developments to clinical trials.
Share of the company's employees Foghorn Therapeutics within the market segment - Cancer blood
Foghorn Therapeutics is a biotech company developing a new class of drugs targeting the chromatin regulatory system. This chart shows the proportion of top-tier scientists in this cutting-edge field of oncology that the company attracts. This reflects its intellectual prowess and the scale of its efforts to create breakthrough cancer treatments.
Number of employees in the market segment - Cancer blood
Foghorn Therapeutics is a biotechnology company developing a new class of drugs to treat cancer by targeting gene regulation. The data presented reflects employment in the oncology research sector. The growing number of scientists in this field indicates high investment activity and the race for scientific breakthroughs, in which Foghorn is at the forefront.
Number of employees in the market as a whole
Foghorn Therapeutics is a biotech company at the forefront of the fight against blood cancer. It develops drugs that regulate gene expression. Its growth is directly linked to scientific breakthroughs and investment in R&D. This chart illustrates overall employment in the economy, where innovative firms like Foghorn are growth drivers, creating highly skilled jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Foghorn Therapeutics (FHTX)
Foghorn Therapeutics is a biotech company at the forefront of cancer science. This chart vividly illustrates a business built on intellectual capital. A small team of highly skilled scientists is working on developing breakthrough drugs, and the market values their potential. The high market capitalization per employee suggests that investors place their faith in the future value of their developments, not their current assets.
%20of%20the%20company%20Foghorn%20Therapeutics%20(FHTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Foghorn-Therapeutics-FHTX&v=1772675369704 "Chart of market capitalization per employee (in thousands of dollars) of the company Foghorn Therapeutics (FHTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Foghorn Therapeutics is a biotech company focused on gene regulation for cancer treatment. Here, value is created not by mass production, but by the intellectual labor of a small team of scientists. The chart shows how highly the market values the potential of their discoveries per employee, a key indicator for science-intensive companies.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772675369718 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Foghorn Therapeutics is a biotech company at the forefront of cancer research, whose value lies in its scientific platform. This chart shows the company's high market valuation per employee, which reflects not current revenue but investors' faith in its R&D potential. This is the value of the intellectual capital concentrated in its scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772675369727 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Foghorn Therapeutics (FHTX)
Foghorn Therapeutics (FHTX) is an R&D-stage biopharmaceutical company focused on oncology. In this business, "employees" are highly skilled scientists. This graph likely shows a negative value—the "capital burn" per researcher. Its dynamics are important: investors are monitoring how investments in intellectual capital will potentially convert into profits after drug approval.
%20Chart%20Foghorn%20Therapeutics%20(FHTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Foghorn-Therapeutics-FHTX&v=1772675369760 "Company Profit Per Employee (in thousands of dollars) Chart Foghorn Therapeutics (FHTX)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Foghorn Therapeutics is a biotech company developing drugs to treat cancer by targeting gene regulation. Their key R&D asset is their team of world-class scientists. This chart shows an industry benchmark that helps assess how effectively Foghorn is leveraging its intellectual capital to create future value.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772675369773 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Foghorn Therapeutics is a biopharmaceutical company focused on gene regulation for cancer treatment. As with most biotech R&D efforts, the "profit" here is often negative. This chart illustrates not current profitability, but rather the investment (R&D costs) per scientist. The bet is that the discoveries of a small team will lead to the creation of intellectual property worth billions.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772675369796 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Foghorn Therapeutics (FHTX)
Foghorn Therapeutics is a clinical-stage biotech company developing cancer drugs. This chart reflects its current focus. Low or zero revenue per employee is typical for R&D companies, whose value is created in the lab rather than through sales, and can change dramatically with the success of a drug.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Foghorn-Therapeutics-FHTX&v=1772675369811 "Sales chart per company employee Foghorn Therapeutics (FHTX)")
Sales per employee in the market segment - Cancer blood
Foghorn Therapeutics (FHTX) is a clinical-stage biotech company specializing in "chromatin regulation" for the treatment of blood cancer. This graph shows how much revenue (from partnerships) each employee (scientist) generates. For a biotech without a product, this is an indicator of the effectiveness of their R&D platform in monetizing early-stage developments.
Sales per employee for the market as a whole
Foghorn Therapeutics is a clinical-stage biotech company focused on cancer treatment. The company has no commercial products and, consequently, no revenue. This chart clearly illustrates the current state: the company incurs expenses on its highly qualified scientists, so the revenue figure is close to zero. This figure reflects net investment in R&D in anticipation of a scientific breakthrough.
Short shares by company, segment and market as a whole
Shares shorted by company Foghorn Therapeutics (FHTX)
Foghorn Therapeutics is a biotech company working on a new class of cancer drugs. It's a binary business: either huge success or complete failure. This chart shows the number of bearish bets. Bears are shorting the stock, anticipating failure in key clinical trials, side effects, or FDA denial of approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Foghorn-Therapeutics-FHTX&v=1772675369857 "Short Shares Chart for the Company Foghorn Therapeutics (FHTX)")
Shares shorted by market segment - Cancer blood
Foghorn Therapeutics is a clinical-stage biotech company attacking cancer through an innovative platform (chromatin remodeling). This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Foghorn, which hasn't yet generated revenue, this is a sign of a "drought": raising capital for long-term and expensive research is becoming nearly impossible.
Shares shorted by the overall market
Foghorn Therapeutics (FHTX) is a biotech company developing a new generation of cancer drugs. This is early-stage science, an extremely risky investment. This generalized fear chart is essentially a death sentence for such stocks in the short term. When investors are afraid, the first thing they do is sell speculative biotechs like FHTX.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Foghorn Therapeutics (FHTX)
Foghorn Therapeutics is a biotech company working in the cutting-edge field of "chromatin regulation" for cancer treatment. It's a highly speculative R&D bet. This chart measures the level of hype. It shows when data euphoria (overbought) or platform doubts (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Foghorn-Therapeutics-FHTX&v=1772675369903 "RSI 14 indicator chart for the company's stock Foghorn Therapeutics (FHTX)")
RSI 14 Market Segment - Cancer blood
Foghorn Therapeutics is a biotech company developing a new class of drugs that target the chromatin regulation system, the mechanism that controls gene expression in cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
Foghorn Therapeutics, a biotech company whose fate depends on this schedule, requires a constant influx of capital to fund expensive clinical trials. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like FHTX are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast FHTX (Foghorn Therapeutics)
Foghorn Therapeutics is a biotech company working in the cutting-edge field of "chromatin regulation." They develop cancer treatments by targeting the system that controls gene expression. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this sophisticated R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-FHTX-Foghorn-Therapeutics&v=1772675369953 "A chart showing analyst consensus forecasts for the expected stock price. FHTX (Foghorn Therapeutics)")
The difference between the consensus estimate and the actual stock price FHTX (Foghorn Therapeutics)
Foghorn Therapeutics is a biotech company attempting to treat cancer by targeting the chromatin system, the mechanism that controls gene expression. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their faith in this complex science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-FHTX-Foghorn-Therapeutics&v=1772675369957 "A chart showing the difference between the consensus forecast and the actual stock price. FHTX (Foghorn Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Foghorn Therapeutics is a biotech company at the forefront of science. It develops drugs that "repair" chromatin (the structure of DNA) to treat cancer. This chart shows the overall expectations for the blood cancer sector, reflecting the confidence experts have in this sophisticated R&D platform.
Analysts' consensus forecast for the overall market share price
Foghorn Therapeutics is a biotech company specializing in "chromatin regulation" (DNA access) to develop a new class of cancer drugs. This chart shows the overall risk appetite. For Foghorn, working in one of the most advanced and risky areas of oncology, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Foghorn Therapeutics
Foghorn Therapeutics (FHTX) is a biotech company working in the cutting-edge field of chromatin regulation. They develop drugs that target not the gene itself, but the mechanism that turns it on or off, primarily for cancer treatment. This graph is a pure assessment of their R&D platform. Its dynamics depend entirely on their progress in clinical trials.
AKIMA Market Segment Index - Cancer blood
Foghorn (FHTX) is a clinical-stage biotech and a pioneer in epigenetics; the company is developing a new generation of drugs that bypass DNA and instead correct gene regulation (for the treatment of blood cancers). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (R&D platform) model (FHTX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Foghorn Therapeutics is a biotech company pioneering the field of "chromatin regulation." It develops drugs that control gene expression in cancer. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding this fundamentally new scientific platform.
